PTC Therapeutics (PTCT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Eric Joseph from J.P. Morgan maintained a Buy rating on the stock and has a $72.00 price target.
Eric Joseph has given his Buy rating due to a combination of factors including PTC Therapeutics’ promising late-stage clinical catalysts and regulatory updates. The company is on track with its US regulatory filings for sepiapterin in PKU and vatiquinone in FRDA, with PDUFA dates set for mid-2025. This positions the company well for potential accelerated approval if clinical correlations are demonstrated.
Additionally, PTC Therapeutics has a solid commercial foundation with its existing products like Translarna and Emflaza, which provide a financial backstop. The company’s revenue guidance for 2025 reflects expectations of contributions from new product launches, despite conservative assumptions from the market. Eric Joseph’s valuation also considers the long-term commercial potential of sepiapterin and votoplam, supporting a price target of $72 by December 2025.
Based on the recent corporate insider activity of 40 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of PTCT in relation to earlier this year.